AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29134789 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS on left dorsolateral prefrontal cortex
Number of subjects: 50
Study 29134789 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS on right dorsolateral prefrontal cortex
Number of subjects: 50
Study 29134789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS on left dorsolateral prefrontal cortex
Number of subjects: 50
Study 29134789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS on right dorsolateral prefrontal cortex
Number of subjects: 50
Study 29134789 — intervention group
Group type: COMPARATOR
Intervention: Active sham rTMS on P3 region
Number of subjects: 50
Study 25286889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water (10º C)
Number of subjects: 10
Study 25286889 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water (37º C)
Number of subjects: 10
Study 25286889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 10
Study 22933433 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fructose (MF) at 40 g/day
Number of subjects: 9
Study 22933433 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose (HF) at 80 g/day
Number of subjects: 9
Study 22933433 — intervention group
Group type: COMPARATOR
Intervention: High glucose (HG) at 80 g/day
Number of subjects: 9
Study 22933433 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose (HS) at 80 g/day
Number of subjects: 9
Study 21909500 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiannual topical fluoride application (elmex fluid)
Number of subjects: 334
Study 21909500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride application)
Number of subjects: 334
Study 21909500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride scores (intervention)
Number of subjects: 334
Study 21909500 — intervention group
Group type: COMPARATOR
Intervention: Fluoride scores (control)
Number of subjects: 334
Study 19426833 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 24
Study 19426833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16507801 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg subcutaneously daily for 5 days)
Number of subjects: 114
Study 16507801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 14725512 — intervention group
Group type: EXPERIMENTAL
Intervention: IM midazolam 0.04 mg.kg(‐1) (Group M1)
Number of subjects: 45
Study 14725512 — intervention group
Group type: EXPERIMENTAL
Intervention: IM midazolam 0.08 mg.kg(‐1) (Group M2)
Number of subjects: 45
Study 14725512 — intervention group
Group type: COMPARATOR
Intervention: No premedication (Group C)
Number of subjects: 45
Study 11547910 — intervention group
Group type: EXPERIMENTAL
Intervention: Different orienting tasks and materials in the familiarization and critical presentations
Number of subjects: 0
Study 11547910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenacted encoding during familiarization
Number of subjects: 0
Study 11547910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted encoding during familiarization
Number of subjects: 0
Study 11547910 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects reported experiencing source discrimination difficulties
Number of subjects: 0
Study 9048536 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (30 mg)
Number of subjects: 10
Study 9048536 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cromolyn (30 mg)
Number of subjects: 10
Study 7864916 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization treatment
Number of subjects: 365
Study 7864916 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 365
Study 3513411 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia with 24 hours of bed rest
Number of subjects: 158
Study 3513411 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia with mobilization
Number of subjects: 158
Study 3513411 — intervention group
Group type: COMPARATOR
Intervention: Standardised spinal anaesthesia with 24 hours of bed rest (surgeon's choice)
Number of subjects: 158
Study 3513411 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia
Number of subjects: 158
Study 3513411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients predisposed to headache, lumbar pain, and visual disturbances
Number of subjects: 158
Study 3513411 — intervention group
Group type: EXPERIMENTAL
Intervention: All newly developed symptoms
Number of subjects: 158
Study 31506240 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwriting exercise (4-week duration using a handwriting practice book)
Number of subjects: 46
Study 31506240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no handwriting exercise)
Number of subjects: 46
Study 31506240 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwriting exercise
Number of subjects: 46
Study 29861245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based mat exercises (twice per week, 60-min per session for 16 weeks)
Number of subjects: 61
Study 29861245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 26605991 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily
Number of subjects: 950
Study 26605991 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 950
Study 26605991 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 950
Study 26182769 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 148
Study 26182769 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 148
Study 24050312 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 (30, 100, 300 mg) every 2 weeks for 24 weeks
Number of subjects: 329
Study 24050312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 24050312 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 (combined)
Number of subjects: 329
Study 24050312 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 (30 mg, 100 mg, 300 mg)
Number of subjects: 329
Study 21048530 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood real-time PCR assay
Number of subjects: 219
Study 21048530 — intervention group
Group type: COMPARATOR
Intervention: Plasma PCR assay
Number of subjects: 219
Study 18512199 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Diabetes DMP
Number of subjects: 3546
Study 18512199 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in Diabetes DMP
Number of subjects: 3546
Study 16556138 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate treatment (oral, prior to sleep on dialysis days for 23 months)
Number of subjects: 21
Study 16556138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no etidronate treatment)
Number of subjects: 21
Study 16556138 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate treatment
Number of subjects: 21
Study 14986872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced version of NIDA standard HIV Intervention
Number of subjects: 0
Study 14986872 — intervention group
Group type: COMPARATOR
Intervention: Focused Intervention based on a cognitive thought‐mapping model
Number of subjects: 0
Study 10630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 0
Study 10630936 — intervention group
Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 0
Study 10630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of the proximal segment
Number of subjects: 0
Study 10630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the mandibular plane
Number of subjects: 0
Study 9004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of 33-40% in daily dosage
Number of subjects: 30
Study 9004050 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of 60-66% in daily dosage
Number of subjects: 30
Study 9004050 — intervention group
Group type: COMPARATOR
Intervention: No reduction (control group)
Number of subjects: 30
Study 8207316 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 302
Study 8207316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 3430969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic dialysis (blood temperature 25 degrees C)
Number of subjects: 9
Study 3430969 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (blood temperature 35 degrees C)
Number of subjects: 9
Study 29546401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study 29546401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28104903 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction therapy with the Saunders device
Number of subjects: 174
Study 28104903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 174
Study 26025383 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS treatment (30 minutes each day for 4 consecutive days during HDBR)
Number of subjects: 14
Study 26025383 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 days HDBR without countermeasures)
Number of subjects: 14
Study 23925377 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cell (MSC) therapy, administered as three transfusions at 1-month intervals over 12 months.
Number of subjects: 13
Study 23925377 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group), administered in parallel to six patients.
Number of subjects: 13
Study 21936892 — intervention group
Group type: EXPERIMENTAL
Intervention: EGML (2 g/day)
Number of subjects: 86
Study 21936892 — intervention group
Group type: EXPERIMENTAL
Intervention: GCE (2 g/day)
Number of subjects: 86
Study 21936892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, 2 g/day)
Number of subjects: 86
Study 17625035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyposis patients
Number of subjects: 28
Study 17625035 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study 17625035 — intervention group
Group type: COMPARATOR
Intervention: Nasal polyposis patients vs Control subjects
Number of subjects: 28
Study 16608033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus thymosin alpha1 therapy postoperatively
Number of subjects: 33
Study 16608033 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy only (Control)
Number of subjects: 33
Study 14552498 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills Training (ST) for 3 months
Number of subjects: 92
Study 14552498 — intervention group
Group type: COMPARATOR
Intervention: Customary Outpatient Care (CC)
Number of subjects: 92
Study 12889398 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer air-cell overlay
Number of subjects: 82
Study 12889398 — intervention group
Group type: COMPARATOR
Intervention: Single-layer air-cell overlay
Number of subjects: 82
Study 12889398 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 82
Study 10465485 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level Mittelmeier osteotomy (Group A)
Number of subjects: 63
Study 10465485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral closed wedge high tibial osteotomy using AO/ASIF L-plate (Group B)
Number of subjects: 63
Study 8609324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone, 5 mg/kg body weight in 30 min followed by 1,200 mg over 24 h
Number of subjects: 100
Study 8609324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 100
Study 8609324 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study 1921738 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg daily for 24 months)
Number of subjects: 38
Study 1921738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6311914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose IFN-alpha 2 (11.4 X 10(6) IU four times per day for four days)
Number of subjects: 2
Study 6311914 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily treatment of IFN-alpha 2 (42.8 X 10(6) IU once per day for five days)
Number of subjects: 2
Study 6311914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage regimens of IFN-alpha 2
Number of subjects: 2
Study 6311914 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2
Number of subjects: 2
Study 3885670 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 (PGE2) vaginal suppositories
Number of subjects: 300
Study 3885670 — intervention group
Group type: COMPARATOR
Intervention: Intranasal oxytocin
Number of subjects: 300
Study 3885670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method of 3 mg PGE2 vaginal suppositories alternating with intranasal oxytocin
Number of subjects: 300
Study 30451392 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 30
Study 30451392 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of participants in the immediate intervention group
Number of subjects: 30
Study 28272029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Continuous Intestinal Loop Warming (ICLW)
Number of subjects: 100
Study 28272029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICLW)
Number of subjects: 100
Study 28272029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 25819645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision (PFN)
Number of subjects: 51
Study 25819645 — intervention group
Group type: COMPARATOR
Intervention: Expanded port site incision (EPS)
Number of subjects: 51
Study 24139548 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine treatment at home using a video conference system with monitoring equipment (spirometer, thermometer, pulse oximeter) and 24/7 online access to the hospital.
Number of subjects: 0
Study 24139548 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment at the hospital.
Number of subjects: 0
Study 20722752 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-sparing arm (zidovudine/lamivudine+efavirenz)
Number of subjects: 63
Study 20722752 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-sparing arm (lopinavir/ritonavir+efavirenz)
Number of subjects: 63
Study 19050084 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg x kg(‐1) morphine
Number of subjects: 40
Study 19050084 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 16550736 — intervention group
Group type: EXPERIMENTAL
Intervention: Content of capsule sprinkled on applesauce (Medikinet retard 20 mg)
Number of subjects: 12
Study 16550736 — intervention group
Group type: COMPARATOR
Intervention: Intact capsule (Medikinet retard 20 mg)
Number of subjects: 12
Study 12569218 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based (CB) program
Number of subjects: 34
Study 12569218 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based (HB) program
Number of subjects: 34
Study 10843243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in MC or mild MesP nephrosis
Number of subjects: 51
Study 10843243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in steroid resistant, MesP nephrosis
Number of subjects: 51
Study 10843243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in nephrosis with FSGS
Number of subjects: 51
Study 9386883 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice (5 minutes)
Number of subjects: 159
Study 9386883 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 30-minute sessions with a physician using cognitive behavioural strategies
Number of subjects: 159
Study 9386883 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 30-minute sessions with a nurse practitioner using identical strategies
Number of subjects: 159
Study 9386883 — intervention group
Group type: COMPARATOR
Intervention: Overall reduction in quantity and frequency of drinking
Number of subjects: 159
Study 8383518 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rac-atenolol
Number of subjects: 12
Study 8383518 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg (S)-atenolol
Number of subjects: 12
Study 8383518 — intervention group
Group type: COMPARATOR
Intervention: 50 mg (R)-atenolol
Number of subjects: 12
Study 8383518 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-atenolol
Number of subjects: 12
Study 8383518 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-atenolol
Number of subjects: 12
Study 2876770 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (Tice) injected intrapleurally between days 6 and 12 postoperatively, with isoniazid given orally for 12 weeks.
Number of subjects: 441
Study 2876770 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline injected intrapleurally.
Number of subjects: 441
Study 2876770 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment.
Number of subjects: 441
Study 2876770 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment in pneumonectomized patients.
Number of subjects: 441
Study 2876770 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment vs placebo in lobectomies.
Number of subjects: 441
Study 31238312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed based on 8 identified risk factors for pancreatic stones in CP patients.
Number of subjects: 2153
Study 31238312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative rates of pancreatic stones after the onset of CP and after the diagnosis of CP.
Number of subjects: 2153
Study 31238312 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified through Cox proportional hazards regression model.
Number of subjects: 2153
Study 29880427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 20 µg/kg/min) and Nitroglycerin (0.5 to 3 µg/kg/min)
Number of subjects: 40
Study 29880427 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (loading dose of 50 µg/kg over 10 minutes, followed by maintenance dose of 0.25 to 0.75 µg/kg/min)
Number of subjects: 40
Study 29880427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dobutamine/Nitroglycerin and Milrinone)
Number of subjects: 40
Study 27771263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodistention with joint manipulation under interscalene block
Number of subjects: 121
Study 27771263 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injection
Number of subjects: 121
Study 24164167 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional stainless steel crown (SSC)
Number of subjects: 76
Study 24164167 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic crown
Number of subjects: 76
Study 24164167 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (not restored)
Number of subjects: 76
Study 22622705 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training for 4 weeks, 1 hour a day, 5 days a week using both cochlear implant and hearing aid devices.
Number of subjects: 7
Study 20820984 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 45 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Number of subjects: 78
Study 20820984 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 180 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Number of subjects: 78
Study 18848791 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation without sapheno-femoral junction ligation
Number of subjects: 43
Study 18848791 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation with sapheno-femoral junction ligation
Number of subjects: 43
Study 16644021 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS) with a positivity threshold of 9.5/30
Number of subjects: 815
Study 16644021 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk markers identified through multivariate risk analysis
Number of subjects: 815
Study 16644021 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS score >10
Number of subjects: 815
Study 14654262 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 26
Study 14654262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10719390 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist diabetes education program led by specialists and a dietician
Number of subjects: 75
Study 10719390 — intervention group
Group type: COMPARATOR
Intervention: General practice diabetes education program performed by a doctor's assistant
Number of subjects: 75
Study 10719390 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluated support program addressing psychosocial impediments
Number of subjects: 75
Study 9110111 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline bromide, 64.3 (+/‐ 21.8) mg/day for 7 days, followed by 30 mg orally before repeat tilt-table testing.
Number of subjects: 16
Study 9110111 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline bromide treatment
Number of subjects: 16
Study 1514336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose spinal anaesthesia with 3 ml of plain 0.5% bupivacaine (SDSA group)
Number of subjects: 40
Study 1514336 — intervention group
Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia using a 32- or 22-gauge catheter with a bolus of 1.0 ml or 0.5 ml of plain 0.5% bupivacaine followed by an infusion at a rate of 2 ml/h (CSA group)
Number of subjects: 40
Study 1514336 — intervention group
Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia (CSA group)
Number of subjects: 40
Study 1514336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose spinal anaesthesia (SDSA group)
Number of subjects: 40
Study 3906163 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean phospholipid (18 g daily for 6 weeks)
Number of subjects: 20
Study 3906163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20